Anadys Pharmaceuticals, Inc.

Scriptgen Pharmaceuticals, Inc.

Other

Applera Corporation

Arqule, Inc.

Bioscale, Inc.

Anadys Pharmaceutical, Inc.

Jaime E Arenas

James W Lillie

Andrew A Pakula

Sharon T Cload

Lance Gavin Laing

David S Casebier

Brett P Masters

Michael Francis Miller

Alison Sparks

Rouh-Rong Juo

Joseph C Hogan, Jr

Lara Madison

Robert Anthony Zambias

Paul Furth

Ricky F Baggio

Cheng Tu

Yi Bin Xiang

David A Bolten

Wayne U Wang

William Emerson Martinez

William Matthew Dickerson

Elizabeth S Fleming

Hyun-Goo Choi

Monica Lozano

Sarah Beth Hembree

Ngo Yim Wong

Gertrude M Gutierrez

Disclosed herein are methods and devices for a cell-free assay platform that enables measurement of membrane protein function by measuring the events that are induced by ligand binding or other stimuli.

Quantitative measurement of membrane protein function on a biosensor

The technology provided herein generally relates to reusable detection surfaces and methods for reusing a detection surface after using the detection surface in an assay for an analyte.

Reusable detection surfaces and methods of using same

The invention pertains to bioconjugation systems comprising sterically constrained cis-diols and borates.

Constrained cis-diol-borate bioconjugation system

The present invention provides methods for screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve assessing the stability and/or the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA stability and/or conformation. In a preferred embodiment, the effect of a ligand on target RNA stability and/or conformation is assessed by measuring the fluorescence polarization of a fluorescently labeled probe.

Screen employing fluorescence anisotropy to identify compounds with affinity for nucleic acids

The present invention provides methods for high-throughput screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve measuring the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA conformation.

Screen for compounds with affinity for nucleic acids

The present invention provides pharmaceutical formulations comprising 1,3,5-triazine derivatives. The compounds and formulations of the present invention exhibit a range of activities, including antiviral and antibiotic activities, and the formulations may be used, alone or in combination, as a method of treating a patient in need of antiviral and/or antibiotic therapy. The triazine derivatives of the present invention bind to and inhibit functional nucleic acids, and hence, have broad applicability in the treatment of conditions associated with DNA and RNA viruses.

Triazine antiviral compounds

An n.times.m.times.p array of different chemical compounds, each having the following scaffold structure: ##STR1## wherein n, m and p are integers, A, B and C are organic structural moieties representing diversity elements. The novel compounds present in this array are useful as inhibitors of binding of Rev protein to a Rev response element.

Combinatorial synthesis and high-throughput screening of a

Growing community of inventors

Lexington, MA, United States of America

Jaime E Arenas